APA

Aapro M., Ruiz-Borrego M., Hegg R., Kukielka-Budny B., Morales S., Cinieri S., Freitas-Junior R., Garcia-Estevez L., Szombara E., Borges G. S., Passalacqua R., Hervieu H., Groc M. & Villanova G. (20191203). Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial). : Breast (Edinburgh, Scotland).

Chicago

Aapro Matti, Ruiz-Borrego Manuel, Hegg Roberto, Kukielka-Budny Bozena, Morales Serafin, Cinieri Saverio, Freitas-Junior Ruffo, Garcia-Estevez Laura, Szombara Ewa, Borges Giuliano Santos, Passalacqua Rodolfo, Hervieu Helene, Groc Mélanie and Villanova Gustavo. 20191203. Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial). : Breast (Edinburgh, Scotland).

Harvard

Aapro M., Ruiz-Borrego M., Hegg R., Kukielka-Budny B., Morales S., Cinieri S., Freitas-Junior R., Garcia-Estevez L., Szombara E., Borges G. S., Passalacqua R., Hervieu H., Groc M. and Villanova G. (20191203). Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial). : Breast (Edinburgh, Scotland).

MLA

Aapro Matti, Ruiz-Borrego Manuel, Hegg Roberto, Kukielka-Budny Bozena, Morales Serafin, Cinieri Saverio, Freitas-Junior Ruffo, Garcia-Estevez Laura, Szombara Ewa, Borges Giuliano Santos, Passalacqua Rodolfo, Hervieu Helene, Groc Mélanie and Villanova Gustavo. Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial). : Breast (Edinburgh, Scotland). 20191203.